
Dr. Marc Gitzinger
Chief Executive Officer, BioVersys AG
BioVersys developed a new mode-of-action antimicrobial, currently in Phase 3 and Phase 2B clinical trials, following meaningful Phase 2 and preclinical results.
Modern healthcare depends on effective antibiotics, yet growing bacterial resistance means we need not just more of them, but genuinely differentiated treatments for pathogens where today’s options are limited. It’s incredible that in 2026, we have so little to fight against the rising pressure of Gram-negative bacteria. That has to change.
Critical-priority pathogen: Acinetobacter baumannii
“Acinetobacter baumannii is a bacterium that can cause severe infections, particularly in critically ill patients,” explains Dr Marc Gitzinger, Chief Executive Officer, BioVersys AG. “Carbapenem-resistant Acinetobacter baumannii, or CRAB, is classified as a critical-priority pathogen, with mortality from serious infections reaching approximately 50%1.”
Our global Phase 3 trial, RIV-TARGET, aims to establish the evidence required for regulatory approval
New mode of action antimicrobials
BioVersys is targeting these alarming pathogens by investigating new mode of action antimicrobials, such as BV100. “BV100 is distinctly different from other antimicrobial drug classes,” explains Dr Gitzinger. “Building on an established active pharmaceutical ingredient, the drug uses a novel mode of action to hijack a bacterial entry pathway, reach its intracellular target and rapidly kill bacteria.”
Results so far are encouraging. “In a cohort of difficult-to-treat ventilated patients, our randomised Phase 2 trial showed mortality falling from 60% with best available therapy to 29% with our drug,” he adds.
Dual Phase 3 and Phase 2b development strategy
BioVersys is advancing BV100 through two parallel clinical trials. “Our global Phase 3 trial, RIV-TARGET, aims to establish the evidence required for regulatory approval,” explains Dr Gitzinger. “The Wellcome-supported Phase 2b RIV-CARE trial will generate additional comparative and real-world evidence.”
BioVersys’ wider pipeline includes a tuberculosis candidate developed with GSK and a programme against chronic lung infections partnered with Shionogi. Dr Gitzinger speaks to positive signs of progress, as the UK’s subscription model and new EU legislation are starting to reward antibiotics for the lives they save, not the volumes sold. “Antibiotics must be used carefully to stay effective,” he says. “Reimbursement that recognises their true value rewards innovation and supports responsible use. These are medicines we cannot afford to lose.”
[1] Sazlly et al 2019 metaanalysis baumannii; Lee et al 2022 mortality CRAB
[2] BioVersys data, available on bioversys.com
Global Cause